TY - JOUR
T1 - Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV
AU - Giron, Leila B.
AU - Palmer, Clovis S.
AU - Liu, Qin
AU - Yin, Xiangfan
AU - Papasavvas, Emmanouil
AU - Sharaf, Radwa
AU - Etemad, Behzad
AU - Damra, Mohammad
AU - Goldman, Aaron R.
AU - Tang, Hsin Yao
AU - Johnston, Rowena
AU - Mounzer, Karam
AU - Kostman, Jay R.
AU - Tebas, Pablo
AU - Landay, Alan
AU - Montaner, Luis J.
AU - Jacobson, Jeffrey M.
AU - Li, Jonathan Z.
AU - Abdel-Mohsen, Mohamed
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Non-invasive biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are urgently needed. Such biomarkers can improve the safety of analytic treatment interruption (ATI) and provide mechanistic insights into the host pathways involved in post-ART HIV control. Here we report plasma glycomic and metabolic signatures of time-to-viral-rebound and probability-of-viral-remission using samples from two independent cohorts. These samples include a large number of post-treatment controllers, a rare population demonstrating sustained virologic suppression after ART-cessation. These signatures remain significant after adjusting for key demographic and clinical confounders. We also report mechanistic links between some of these biomarkers and HIV latency reactivation and/or myeloid inflammation in vitro. Finally, machine learning algorithms, based on selected sets of these biomarkers, predict time-to-viral-rebound with 74% capacity and probability-of-viral-remission with 97.5% capacity. In summary, we report non-invasive plasma biomarkers, with potential functional significance, that predict both the duration and probability of HIV remission after treatment interruption.
AB - Non-invasive biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are urgently needed. Such biomarkers can improve the safety of analytic treatment interruption (ATI) and provide mechanistic insights into the host pathways involved in post-ART HIV control. Here we report plasma glycomic and metabolic signatures of time-to-viral-rebound and probability-of-viral-remission using samples from two independent cohorts. These samples include a large number of post-treatment controllers, a rare population demonstrating sustained virologic suppression after ART-cessation. These signatures remain significant after adjusting for key demographic and clinical confounders. We also report mechanistic links between some of these biomarkers and HIV latency reactivation and/or myeloid inflammation in vitro. Finally, machine learning algorithms, based on selected sets of these biomarkers, predict time-to-viral-rebound with 74% capacity and probability-of-viral-remission with 97.5% capacity. In summary, we report non-invasive plasma biomarkers, with potential functional significance, that predict both the duration and probability of HIV remission after treatment interruption.
UR - http://www.scopus.com/inward/record.url?scp=85108956263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108956263&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-24077-w
DO - 10.1038/s41467-021-24077-w
M3 - Article
C2 - 34188039
AN - SCOPUS:85108956263
SN - 2041-1723
VL - 12
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 3922
ER -